Give hope this Daffodil Day

For all that cancer takes, give generously

Donate now

Striving for a cancer-free future

New treatments for Acute lymphoblastic leukaemia

Lead researcher

Dr Donia Moujalled

Institution
Monash University

Tumour type:
Leukaemia

Years funded
2018-2020

Acute lymphoblastic leukaemia is a blood cancer that has a poor prognosis due to resistance to current therapies and to relapse.

Targets common to malignant clones are regulated by the BCL2 family of proteins. We have shown that drugs targeting the pro-survival proteins BCL2 and MCL1 can cause cell death in patient samples.

This project will examine the ability of a BCL2 and a MCL1 inhibitor to eradicate acute lymphoblastic leukaemia – either as a single agent or in combination with standard chemotherapy drugs or novel compounds. We will also examine patient samples in a world-first clinical trial for adult patients at The Alfred Hospital.

Funding Body

Cancer Council Victoria Research Grant